(Reuters) – Spectrum Pharmaceuticals Inc said a mid-stage trial of its experimental blood cancer drug met the main goal of shrinking tumors.
The drug, belinostat, was tested in patients with relapsed/refractory peripheral T-Cell (PTCL) lymphoma, who have failed at least one therapy.
The biotechnology company said it expects to file a marketing application with U.S. health regulators by mid-2013, and expects a review date in 2014.
Belinostat was granted orphan-drug status and fast-track status by the U.S. Food and Drug Administration for PTCL.
Spectrum‘s shares, which have fallen about 22 percent in the last year, closed at $ 11.30 on the Nasdaq on Thursday.
(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)
Diseases/Conditions News Headlines – Yahoo! News
Title Post: Spectrum Pharma’s blood cancer drug meets goal in mid-stage trial
Rating:
100%
based on 99998 ratings.
5 user reviews.
Author:
Thanks for visiting the blog, If any criticism and suggestions please leave a comment
Spectrum Pharma’s blood cancer drug meets goal in mid-stage trial
This article
Spectrum Pharma’s blood cancer drug meets goal in mid-stage trial
can be opened in url
http://newsentryes.blogspot.com/2012/12/spectrum-pharmas-blood-cancer-drug.html
Spectrum Pharma’s blood cancer drug meets goal in mid-stage trial
